US Capital Partners Provides $1 Million Line of Credit and $500,000 Term Loan fo

r November Research Group, LLC

US Capital Partners, LLC has put in place financing to support the continued exp
ansion of a global leader in drug safety and pharmacovigilance services and soft
ware tools.
San Francisco, CA, May 07, 2014 -- US Capital Partners, LLC has provided a $1.5
million credit facility for November Research Group, LLC (November Research), head
quartered in Oakland, CA. US Capital Partners is a private investment bank that
makes direct debt investments, participates in debt facilities, and arranges equ
ity placements for small to lower middle market companies.
We are extremely pleased with this well-structured debt financing, which is desig
ned to support our ongoing expansion, said Seth Warhaftig, President of November
Research. Last year, the FDA's Center for Devices and Radiological Health selected
November Research's PRIMO software platform as the product vigilance software solu
tion to replace its aging MAUDE system. Recently, we launched an aggressive camp
aign to expand our products and services into the Japanese market. As we move in
to the next phase of our business expansion, this new credit facility will provi
de the additional working capital we need to support our growth plans.
We are delighted to have provided $1.5 million in financing for this global leade
r in drug safety and pharmacovigilance solutions, said Jeffrey Sweeney, CEO and M
anaging Director at US Capital Partners. November Research is at an inflection po
int in its development and required additional capital to take advantage of exci
ting new growth opportunities for the business. US Capital Partners successfully
provided a $1 million line of credit together with a $500,000 term loan to supp
ort the company's ongoing domestic and international expansion.
About November Research Group, LLC
November Research is a professional services firm that provides a complete spect
rum of software and services in pharmacovigilance to the pharmaceutical and life
science industry. The November Research team possesses extensive expertise span
ning the entire pharmacovigilance industry. The firm's services include drug safet
y business process transformation, solution selection, system implementation and
upgrade, custom software development, and post-implementation support.
About US Capital Partners, LLC:
Since 1998, US Capital Partners (www.uscapitalpartners.net) has been providing p
rompt, innovative, and reliable financing solutions including lending, equity fi
nancing, and debt re-structuring to businesses across the United States and abro
ad. US Capital Partners is a private investment bank, direct lender, co-lender,
and lead financial arranger that specializes in asset-based debt for small to mi
ddle market private and public companies. The company's innovative approach allows
it to provide the best financing available, not only for companies in excellent
financial condition, but also for companies that may have been refused credit b
y traditional lenders.
To learn more about how your business can secure the funding it needs, email Jef
frey Sweeney, CEO and Managing Director, at jsweeney@uscapitalpartners.net or ca
ll (415) 889-1010.
Contact:
Hilary Adams
US Capital Partners, LLC
555 Montgomery Street, Suite 1501
San Francisco, CA 94111
415-889-1010
james@englishwordfactory.com
http://www.uscapitalpartners.net